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ABSTRACT
The effects of molecularly targeted drug perturbations on cellular activities and fates are difficult to predict using intuition
alone because of the complex behaviors of cellular regulatory networks. An approach to overcoming this problem is to
develop mathematical models for predicting drug effects. Such an approach beckons for co-development of computational
methods for extracting insights useful for guiding therapy selection and optimizing drug scheduling. Here, we present and
evaluate a generalizable strategy for identifying drug dosing schedules that minimize the amount of drug needed to achieve
sustained suppression or elevation of an important cellular activity/process, the recycling of cytoplasmic contents through
(macro)autophagy. Therapeutic targeting of autophagy is currently being evaluated in diverse clinical trials but without the
benefit of a control engineering perspective. Using a nonlinear ordinary differential equation (ODE) model that accounts for
activating and inhibiting influences among protein and lipid kinases that regulate autophagy (MTORC1, ULK1, AMPK and
VPS34) and methods guaranteed to find locally optimal control strategies, we find optimal drug dosing schedules (open-loop
controllers) for each of six classes of drugs and drug pairs. Our approach is generalizable to designing monotherapy and multi
therapy drug schedules that affect different cell signaling networks of interest.
Introduction
Although there is much current interest in using combinations of molecularly targeted drugs to improve outcomes for cancer
patients1, 2, relatively little work has been done in the area of formal therapy design, meaning therapy selection and/or scheduling
driven by insights from mathematical models3, 4. Formal approaches to therapy design are potentially useful for at least three
reasons. First, all possible combinations of drugs may be difficult, if not impossible, to evaluate experimentally simply because
of the large number of possible combinations. Second, an ability to extrapolate accurately beyond well-characterized scenarios
with the aid of predictive models would be valuable for individualized treatment, especially in cases where molecular causes
of disease are diverse and vary from patient to patient, as in many forms of cancer5. Third, it is often non-obvious how the
immediate effects of drug perturbations propagate through a cellular regulatory network to affect cellular phenotypes and fates6
or how drug combinations might be deployed to avoid or delay the emergence of resistance, a common response of malignant
cells to targeted therapies7. Predictive models promise to help identify new robust therapies.
Here, we apply mathematical modeling and optimal control methods to design drug schedules for manipulating autophagy,
a stress-relieving/homeostatic cellular recycling process that, when nutrients are in limited supply, generates building blocks
for protein synthesis through degradation of cytoplasmic contents8, such as cytotoxic protein aggregates that are too large for
proteosomal degradation and damaged organelles (e.g., depolarized mitochondria). Autophagy also plays an important role in
immunity9, 10; the autophagic degradative machinery can be directed to target intracellular microbes, such as Mycobacterium
tuberculosis, for destruction.
Cytoplasmic contents that are targeted for autophagic degradation are first trapped in double-membrane vesicles, termed
autophagosomes or autophagic vesicles (AVs), and then delivered to lysosomes for digestion11, 12. The production of AVs
is controlled by an intricate regulatory network, in which three protein kinase-containing complexes are prominent: the
heterotrimeric AMP-activated kinase (AMPK), which senses energy (glucose) supply through interactions with adenosine
derivatives (AMP and ATP)13, 14; MTOR complex 1 (MTORC1), which senses amino acid supply and growth factor signaling
through interactions with small GTPases localized to lysosomal surfaces (Rag proteins and RHEB)15, 16; and the ULK1 complex,
which is activated by AMPK and repressed by MTORC117–19. A fourth complex, which contains a lipid kinase, VPS34, also
plays an important role20, 21. Interestingly, VPS34 and MTOR are phylogenetically related: they are both members of the
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phosphoinositide 3-kinase (PI3K) family. Drugs with specificity for each of these kinases are available, and because of the
relationship between MTOR and VPS34, drugs are also available with dual specifity for this pair of kinases22–24.
In cancer, and other contexts, autophagy is a double-edged sword25. It can protect cancer cells from stresses of the tumor
environment (e.g., lack of nutrients because of defective vasculature) or induce cell death if recycling is excessive. Thus, there
are potential benefits to be gained by using drugs to either upregulate autophagy (to kill malignant cells through excessive
recycling) or downregulate autophagy (to kill cancer cells that rely on autophagy for survival)26.
To investigate how single drugs and drug pairs might be best used for these purposes, we constructed a system of nonlinear
ordinary differential equations (ODE) that captures regulatory interactions between MTORC1, ULK1, AMPK, and VPS34,
as well as the idealized pharmacokinetics of kinase inhibitors specific for MTORC1, ULK1, AMPK, and VPS34, such as
rapamycin27, SBI-020696528, dorsomorphin29, and SAR40530, respectively. We also considered an allosteric activator of AMPK
(e.g., PF-0640957731) and a kinase inhibitor with dual specificity for MTORC1 and VPS34 (e.g., buparlisib32). Although the
model is minimalist by design, it reproduces key behavioral features of earlier, more mechanistically detailed models33, 34, such
as oscillatory responses to intermediate levels of nutrient or energy stress. We then applied optimization methods implemented
in the open-source PSOPT software package35 to find locally optimal dosing schedules that minimize the total amount of
drug needed to drive the network to a desired, non-attracting operating point (corresponding to low or high AV count/turnover)
and maintain it there. The dosing schedules are non-obvious, and synergistic drug pairs were predicted (drug 6 plus drug 1,
2 or 3), such as the combination of a VPS34 inhibitor and a dual specificity PI3K inhibitor, which acts on both VPS34 and
MTORC1. This drug pair requires less total drug to achieve the same effect than either of the individual drugs alone and is
relatively fast acting, which may be important for preventing or slowing the emergence of resistance.
The approach illustrated here differs from earlier applications of control theory concepts in the area of formal therapy
design36–40 in that 1) the system being controlled is a cellular regulatory network, 2) the control interventions are injections (i.e.,
inputs) of (combinations of) molecularly targeted drugs, and 3) the control objective is manipulation of a cellular phenotype,
namely the number of AVs per cell, which is related to the rate of AV turnover, with minimization of total drug used and a
constraint on the maximum instantaneous drug concentration. The rationale for minimizing drug use is to avoid offtarget effects
and associated toxicities. Our work is distinct from earlier studies of (non-biological) nonlinear network control41–44, in that
our control goal is not to drive the system to an attractor (e.g., a stable steady state or limit cycle), but to an arbitrary point in
phase space (i.e., the multidimensional space defined by the state variables of a system) and to then maintain the system there
indefinitely. The approach is both flexible and generalizable and provides a means for computationally prioritizing drug dosing
schedules for experimental evaluation.
Results
Model for cellular regulation of autophagy and the effects of targeted drug interventions
A prerequisite for formal therapy design is a mathematical model that captures the relevant effects of drugs of interest. Given
our interest in using drugs to modify the process of (macro)autophagy, we constructed a model for regulation of the rate of
synthesis of autophagic vesicles (AVs) that accounts for the enzymatic activities and interactions of four kinases that play critical
roles in regulating autophagy, all of which are potential drug targets. The model further considers the effects of achievable drug
interventions and idealized drug pharmacokinetics, meaning instantaneous drug injection according to a time-dependent control
function and first-order clearance. The model is illustrated in Fig. 1.
The model was constructed in two steps. First, we constructed a minimalist model for physiological regulation of
autophagy consistent with key features of earlier, more mechanistically detailed models33, 34 (see “Formulation of the Model” in
Supplementary Methods for details). These features include the time scale of drug-stimulated autophagy induction and the
dynamic range of regulation characterized by Martin et al.34 and the qualitative system behaviors characterized by Szyman´ska
et al.33, including a steady, low level of autophagy at low stress levels, oscillatory behavior at intermediate stress levels, and a
steady, high level of autophagy at high stress levels. Simulations based on the present model—generated through numerical
integration of the equations given below—and simulations based on earlier, related models33, 34 are compared in Supplementary
Fig. S1. Simulations of AV dynamics are compared to measured AV dynamics33 in Supplementary Fig. S2.
The model of Fig. 1 is intended to provide an idealized representation of regulation of AV synthesis in a single (average)
cell in response to changes in the cellular supplies of energy and nutrients, which are treated in the model as external inputs
that modulate the serine/threonine-specific protein kinase activities of AMPK and MTORC1, respectively. Thus, the model
reflects regulation of AMPK activity by the cellular AMP:ATP ratio, which is affected by glucose availability, for example,
and regulation of MTORC1 activity via, for example, the various amino acid-sensing regulators of Ragulator-associated
heterodimeric Rag proteins, which recruit MTORC1 to lysosomes for activation in a manner that depends on their regulated
guanine nucleotide binding states. The model further accounts for regulatory interactions among AMPK, MTORC1, a third
serine/threonine-specific protein kinase ULK1, and a class III phosphoinositide 3-kinase (PI3K) VPS34. As noted earlier, these
kinases are key regulators of autophagy, and each is a potential drug target.
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In the second step of model construction, we added idealized consideration of six distinct drug interventions, which
correspond to interventions achievable through use of available small-molecule compounds, such as rapamycin27 (an inhibitor
of MTORC1 kinase activity), buparlisib32 (an inhibitor of PI3K-family kinases that has specificity for both MTORC1 and
VPS34), SBI-20696528 (an inhibitor of ULK1 kinase activity), dorsomorphin29 (an inhibitor of AMPK kinase activity), PF-
0640957731 (a direct activator of AMPK kinase activity), and SAR40530 (an inhibitor of VPS34 kinase activity). Each drug
i ∈ {1, . . . , 6} (Fig. 1) is taken to be cleared via a pseudo first-order process and introduced in accordance with a specified,
time-dependent injection function ui.
The model was formulated as a coupled system of nonlinear ordinary differential equations (ODEs):
T x˙1(t) = (1− x1)CNuH(w1)H(w2)− x1h12(x2)h13(x3), (1a)
T x˙2(t) = (1− x2)h23(x3)H(w3)− x2h21(x1), (1b)
T x˙3(t) = (1− x3)k1H(w4)− CEnx2x3H(w5), (1c)
T x˙4(t) = (1− x4)h42(x2)H(w2)H(w6)− k2x4, (1d)
T x˙5(t) = k3x4 − k4x5, (1e)
Tw˙i(t) = biui(t)− δiwi(t), i = 1, . . . , 6. (1f)
In these equations, t is time (in min) and T is a timescale, which we specify as 1.0 min. The variable x1 represents the fraction
of MTORC1 that is active, the variable x2 represents the fraction of ULK1 that is active, the variable x3 represents the fraction
of AMPK that is active, the variable x4 represents the fraction of VPS34 that is active, and the variable x5 represents the AV
count or number of AVs per cell (on a continuum scale). Thus, xi always lies somewhere in the interval [0, 1] for i = 1, . . . , 4.
The AV count is bounded 0 ≤ x5 ≤ k3/k4 because x5(t) = 0 implies x˙5(t) ≥ 0 and x5(t) = k3/k4 implies x˙5 ≤ 0 (by the
previously stated bound on x4(t)). The variables w1, . . . , w6 represent the dimensionless concentrations of drugs 1–6. Thus,
wi ≥ 0 for each i. The non-dimensional parameters CEn and CNu are condition-dependent constants that define the supplies of
energy and nutrients. An increase in energy supply is taken to positively influence the rate of deactivation of AMPK, and an
increase in nutrient supply is taken to positively influence the rate of activation of MTORC1. The non-dimensional parameters
k1 and k2 influence the rate of activation of AMPK and the rate of deactivation of VPS34, respectively. The non-dimensional
parameter k3 is the maximal rate of VPS34-dependent synthesis of AVs, and the non-dimensional parameter k4 is the rate
constant for clearance of AVs. Taking the rate of AV synthesis to be proportional to VPS34 activity is consistent with the model
of Martin et al.34, as is (pseudo) first-order clearance of AVs. The non-dimensional parameters δ1, . . . , δ6 are rate constants for
clearance of drugs 1–6. Each hji(xi) is a non-dimensional Hill function that has the following form:
hji(xi) = rb,ji + (rm,ji − rb,ji) x
nji
i
x
nji
i + θ
nji
ji
(2)
where nji (the Hill coefficient), rb,ji, rm,ji and θji are non-negative constants. The h functions account for regulatory influences
among the four kinases considered in the model; the influences considered are the same as those considered in the model of
Szyman´ska et al.33 (cf. Fig. 1 and Figs. 1 and 2 in Ref. 33). Each H(wi) is a non-dimensional Hill function that has the
following form:
H(wi) = rm − (rm − rb) w
n
i
wni + θ
n
(3)
where n (the Hill coefficient), rb, rm and θ are non-negative constants. The H functions account for drug effects on kinase
activities. The parameters bi (i = 1, . . . , 6) in Eq. (1f) are Boolean variables introduced for convenience, for the purpose
of defining allowable drug combinations. Recall that the ui terms represent drug injection/input functions, which will be
determined by solving an optimal control problem (described in the following section).
Parameter settings are summarized in Supplementary Tables S1 and S2. Each δ parameter was assigned a value consistent
with a known drug half-life31, 45–49 (Supplementary Table S2). Other parameters were assigned values that allow the model to
reproduce the qualitative signaling behaviors of the AMPK-MTORC1-ULK1 triad characterized in the theoretical study of
Szyman´ska et al.33 and to reproduce the timescale of autophagy induction and the range of regulation quantified experimentally
in the study of Martin et al.34. According to Szyman´ska et al.33, at low levels of energy/nutrient stress, ULK1 activity, which
can be expected to correlate with autophagic flux and AV count, is steady and low; at intermediate levels of stress, ULK1
activity is oscillatory; and at high levels of stress, ULK1 activity is steady and high. As noted earlier, in Supplementary Fig. S1,
we compare simulations based on Eq. (1) with simulations based on models of Szyman´ska et al.33 and Martin et al.34, and in
Supplementary Fig. S2, we compare simulations of AV dynamics based on Eq. (1) with experimental measurements of AV
dynamics reported by Martin et al.34. Parameter settings are further explained in Supplementary Methods. In Supplementary
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Methods, we also elaborate on how earlier models33, 34 guided our formulation of Eq. (1) and how these models differ from Eq.
(1).
Model-predicted physiological regulation of autophagy, by energy and nutrients, is summarized in Fig. 2. Figure 2A shows
how qualitative long-time behavior depends on the supplies of energy and nutrients, when these supplies are maintained at
constant levels and in the absence of external control inputs (ui = 0, i = 1, . . . , 6). Figures 2B–E show time courses of
autophagy induction or repression triggered by different energy/nutrient changes. All together, these plots show that model
predictions of responses to physiological perturbations (i.e., changes in CEn and CNu) are consistent with expectations based
on the studies of Martin et al.34 and Szyman´ska et al.33.
Dose-response curves predicted by the model for single-drug, constant-concentration perturbations are shown in Fig. 3. As
can be seen, with increasing dosage, drugs 1 and 5 tend to increase the number of AVs per cell, whereas the other drugs tend
to decrease the number of AVs per cell. These results are consistent with negative regulation of autophagy by MTORC1 and
positive regulation of autophagy by ULK1, AMPK, and VPS34. As is the case for some physiological conditions (Fig. 2), AV
count oscillates at some of the drug doses, depending on the supplies of energy and nutrients. All together, the plots shown
in Fig. 3 indicate that responses to single-drug, constant-concentration perturbations are consistent with accepted regulatory
influences of MTORC1, ULK1, AMPK and VPS34 on autophagy.
As can be seen in Fig. 3, the ability of each drug i to influence x5 depends on the supplies of energy and nutrients, meaning
the values of CEn and CNu (cf. the left and right panels in each row). In this figure, two energy/nutrient conditions are
considered (CEn = CNu = 0.1 and 0.6); additional conditions are considered in Supplementary Figs. S3 and S4. Taken
together, these results define the condition-dependent ranges over which x5 can be feasibly controlled by each drug i.
Therapy design as an optimal control problem
To design optimal therapies, we must first introduce design goals. Below, we introduce a series of goals/constraints that we will
require optimal therapies to satisfy. However, let us first introduce notation useful for referring to therapies. We will refer to the
set of six available drugs, or more precisely, drug types, as D = {1, . . . , 6}, and we will refer to a therapy involving k drugs
chosen from D as Tk, where
Tk ⊆ D s.t. |Tk| = k. (4)
Thus, for example, we will use T1 to refer to a monotherapy, and T2 to refer to a dual therapy. There are six possible
monotherapies and, in general, C6k distinct therapies that combine k of the six drugs. Here, we will focus on monotherapies
and dual therapies, leaving the evaluation of higher-order combination therapies for future work. As a simplification, we will
assume that drugs used together in a combination do not interact. Thus, for example, for dual therapy with drugs 2 and 6
(Fig. 1), we consider these drugs to bind/inhibit VPS34 independently (i.e., non-competitively).
Our first, and most important, therapy design goal can be described (somewhat informally) as follows. Starting from a
stationary (or recurrent) state at time t = 0, we wish to use drug injections (i.e., drug inputs) according to a schedule defined
by u(t) = (u1(t), . . . , u6(t)) to eventually maintain, after a transient of duration t0, the number of AVs in an average cell,
x5, near (to within a tolerance ) a specified target level, x
f
5 , for a period of at least tf − t0 (tf > t0 > 0), thereby achieving
sustained control of the level of autophagic degradative flux in a cell, which is given by k4x5 according to Eq. (1). In our
analyses, we will consider t0 = 120 min and tf = 240 min because these times are longer than typical transients (Figs. 2B–E).
A second therapy design goal of interest is minimization of the total amount of drug used, which is motivated by a desire to
avoid drug toxicity arising from dose-dependent offtarget effects. In the optimal control literature, a problem entailing this type
of constraint is called a minimum fuel problem50, 51. The constraint can be expressed mathematically as follows:
min
ui(t),
i∈Tk
J {ui} :=
∑
i∈Tk
∫ tf
0
ui(t) dt (5)
where ui(t) ≥ 0 for i = 1, . . . , 6. As a simplification, we are considering an objective functional J {ui} that treats the different
drugs equally, i.e., the sum in Eq. (5) is unweighted. With this approach, we are assuming that the different drugs of interest
have equivalent toxicities. If drugs are known to have different toxicities, this assumption can be lifted simply by introducing
weights to capture the toxicity differences, with greater weight assigned for greater toxicity. Indeed, arbitrary modifications of
the form of the objective functional J {ui} would be feasible if such modifications are needed to capture problem-specific
constraints on drug dosing.
A third design goal is to disallow the instantaneous concentration of any drug i, wi(t), from ever rising above a threshold
wmaxi . The rationale for this constraint is again related to a desire to eliminate or minimize dose-dependent drug toxicity. In
other words, we are assuming that a drug i is tolerable so long as its concentration wi is below a toxicity threshold wmaxi . In our
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analyses, we set the toxicity threshold of a drug as a factor (> 1) times its EC50 dosage, which we define as the concentration
of the drug at which its effect on x5, negative or positive, is half maximal (see Eqs. (2) and (3)).
We are now prepared to formulate the problem of (combination) therapy design as a constrained, optimal control problem.
The problem, for a given Tk (Eq. (4)), is to find a drug schedule u(t) that minimizes the objective functional defined in Eq. (5)
and that also satisfies the following constraints:
X˙(t) = f(X(t),u(t)), 0 ≤ t ≤ tf , (6a)
bi =
{
1, if i ∈ Tk,
0, otherwise,
(6b)
xf5 −  ≤ x5(t) ≤ xf5 + , t0 ≤ t ≤ tf , (6c)
0 ≤ wi(t) ≤ wmaxi , i = 1, . . . , 6, (6d)
0 ≤ ui(t), i = 1, . . . , 6, (6e)
X(0) = [x(0),w(0)] ≡ [x0, 0]. (6f)
Here, X(t) is defined as [x(t),w(t)], where x(t) = (x1(t), . . . , x5(t)) and w(t) = (w1(t), . . . , w6(t)), and f(X(t),u(t)) is the
vector field of Eq. (1). The initial condition X0 = X(0) is taken to be a stationary (or recurrent) state of Eq. (1) where supplies
of energy and nutrients are constant (i.e., CEn and CNu are fixed) and drugs are absent (i.e., u(t) = 0). With this formulation, it
should be noted that we are attempting to drive the system variable x5 to a specified final value x
f
5 (to within a tolerance ), but
we are making no attempt to control the other system variables x1, x2, x3, and x4. This approach is called target control52, 53.
In all of our analyses, we set  = 1.
A useful measure of the amount of ‘fuel’ used to achieve drug control of autophagy is the total dosage of drug i used up to
time t during a therapy Tk, which we denote as r∗i,k(t). This quantity is calculated using
r∗i,k (t) =
∫ t
0
u∗i (τ)dτ, (7)
where u∗i (t) for i ∈ Tk is the solution of the nonlinear optimal control problem defined by Eqs. (5) and (6).
Optimal monotherapies
We will illustrate generic features of solutions to the nonlinear optimal control problem defined by Eqs. (5) and (6) by focusing
on a particular (severe) energy/nutrient stress condition (i.e., the condition where CNu = CEn = 0.1). For this condition, the
system represented by Eq. (1) has a near maximal, steady-state AV count of approximately 37 per cell (i.e., x5 ≈ 37). Let us
focus for the moment on monotherapy with drug 4 (an AMPK inhibitor) to downregulate the number of AVs to a target level of
10 per cell (i.e., xf5 = 10) over the time period between t0 = 120 min and tf = 240 min from an unperturbed steady state (i.e.,
dynamics with ui = 0) at t = 0.
We solved the optimal control problem using the approach outlined in the Methods section and described in more detail in
“Pseudo-Spectral Optimal Control” in Supplementary Methods. The solution, represented by the optimal cumulative dosage of
drug 4 (i.e., r∗4,1 (t)) (Eq. (7)), is presented in Fig. 4A. The optimal solution exhibits several generic features of the system’s
dynamics, regardless of its parameterization. First, the computation suggests an optimal earliest time to apply the drug. In
this particular example, this time is t . 60 min. The difference between the target time t0 and the earliest time to apply the
drug quantitatively measures the speed of action of the drug. Secondly, the function r∗4,1 (t) exhibits a staircase behavior,
indicating that the optimal strategy of drug administration for this particular problem is to intermittently inject a specific dosage
of drug into the system at specific times. Mathematically, this is due to the fact that the objective functional (Eq. (5)) is a linear
combination of the L1 norm of the injection/input rate ui’s—see Sections 5.5 and 5.6 in Kirk50.
Figure 4B depicts how the drug concentration w4(t) evolves subject to the optimal protocol u∗4(t). We observe surges of
w4(t) in response to the drug being applied to the system in large quantities over small intervals, and slow decays in between
applications of the drug (caused by the natural decay of the drug concentration in the absence of external drug inputs dictated
by δi.) As a consequence, the optimal solution is to inject a relatively large dose of a drug periodically, and to continuously
supply small amounts of that drug to replenish drug cleared from the system to stably maintain autophagic flux (i.e., constant
AV count and constant degradative flux, which we take to be proportional to the AV count).
Figure 4C illustrates the time evolution of x5 (AV count) subject to the optimal drug administration protocol. As can be seen,
for t ≥ 120 min, x5 is maintained within the desired interval x5f ±  = 10± 1. The time evolution of the non-target variables
x1, x2, x3 and x4 (i.e., the activities of the regulatory kinases) are presented in Fig. 4D. Together, Figs. 4C and D provide a
full representation of the time evolution of the system represented by Eq. (1) (the target and non-target variables) under the
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influence of the optimal drug administration schedule. Because our procedure to find the optimal solution to the nonlinear
optimal control problem is numerical, we have verified that the optimal control solution satisfies the necessary conditions that it
must satisfy for optimality. See “Pseudo-Spectral Optimal Control” in Supplementary Methods for details.
Given that cancer cells may be killed by using drugs to either elevate or suppress autophagy26, we will now consider optimal
control solutions that either upregulate or downregulate autophagic flux by using a single drug. We will identify the drugs which
can perturb and maintain the system near the target AV count. Perhaps more importantly, our analysis will deliver optimal
protocols which include the precise times to inject the drugs, whose dosages are also tightly controlled to minimize the total
quantities of drugs that are supplied.
Let us consider the case of intermediate energy/nutrient stress before treatment (i.e., the condition corresponding to
CNu = CEn = 0.6; see Fig. 2), for which the system exhibits oscillations in the range [20, 27] without treatments. For this
scenario, our goal is to either downregulate the number of AVs to xf5 ≈ 9 (shown in Figs. 4E–H) or to upregulate the AVs to
xf5 ≈ 37 (shown in Figs. 4I–L). We have performed extensive numerical solutions of the monotherapy optimal control problem
with various settings of the parameters wmaxi , t0, tf and x
f
5 . We set the control window in the interval between t0 = 120 min
and tf = 240 min and imposed a constraint on each drug concentration wi, requiring it not to exceed wmax = 4× EC50.
We found drug 2 to be best suited for downregulation for two reasons. First, drug 2 is able to drive x5 nearly to zero
(in contrast with the case for drug 3 or 4). See Figs. 2B and 2H and compare with Figs. 2C, 2D, 2I, and 2J. Second, drug
2 (in contrast with drug 6) is able to overcome the autonomous oscillatory behavior in x5. In the analysis summarized in
Supplementary Fig. S7, we found that drug 6 cannot eliminate oscillatory behavior; thus, it is incapable of maintaining a low,
steady AV level. Drug 6 becomes viable if we remove the lower bound from the constraint of Eq. (6c). Without the lower bound,
oscillations in x5 are permitted. We choose to keep the constraint of Eq. (6c) as written to avoid oscillatory solutions because,
depending on period and amplitude, oscillations in x5 may allow for autophagy-addicted cells to survive periods of relatively
low autophagy by thriving during periods of relatively high autophagy. In the other direction (i.e., drug-induced upregulation of
autophagy), it is only possible to use drug 5 to upregulate autophagy to the target value xf5 = 37 (Fig. 3). Figs. 4E–H and 4I–L
illustrate the optimal solutions using drugs 2 and 5 to downregulate and upregulate autophagy, respectively.
Although the selection of a single drug to achieve a given qualitative change in x5 is intuitive, especially given the results of
Fig. 3, optimization of drug scheduling (Fig. 4) delivers better solutions in the sense that the total dosage applied to achieve
the same effect (compared to constant input) is lower (minimized). Furthermore, the generic staircase-like solutions for r∗i,k
illustrated in Fig. 4 persist for all the parameter sets we have tested (see below), indicating that variable, tightly controlled
dosages should be injected into the system at controlled times. Given a particular type of drug, the central result of our optimal
control analysis is to provide injection/input times and the amounts of drugs to be injected/added.
Optimal combination therapies
Let us now consider dual therapies (k = 2). The motivation is to identify therapies—protocols involving lower quantities of
drugs and faster responses—that are even more efficient than optimal monotherapies. We have evaluated all possible dual
therapies (C62 = 15) for each of two energy/nutrient stress conditions: CEn = CNu = 0.1 (corresponding to severe stress)
and CEn = CNu = 0.6 (corresponding to moderate stress). With an identical control objective and identical constraints
wmaxi = 2.0 t0 = 120, tf = 240, x
f
5 = 10, and  = 1, we found four pairs of drugs that are each more efficient than the optimal
monotherapy with either of the two drugs included in the combination. These dual therapies are illustrated in Fig. 5. Additional
results from our analyses of dual therapies are presented in the Supplementary Note and Supplementary Figs. S3–S10.
We found that when baseline autophagy is high (CEn = CNu = 0.1), the only combination of drugs that can drive AV count
down to the target xf5 is the combination of drugs 2 and 6. The dynamical response of the system is shown in Figs. 5A–D. For
this particular combination, either drug alone cannot lower x5 to 10 without violating one or both of the constraints wi < wmaxi
(i = 2, 6). However, with use of drugs 2 and 6 in combination, it is possible to achieve the target AV count because the effects
of the drugs are multiplicative (Eq. (1d)) and drug 2 directly affects both MTORC1 (Eq. (1a)) and VPS34 (Eq. (1d)).
Our analysis predicts non-trivial synergistic activities between drugs when the baseline level of autophagy is intermediate
(on average) and exhibits oscillatory behavior (CEn = CNu = 0.6). The results are summarized in Figs. 5E–P. In this scenario,
multiple drug combinations (drugs 1 and 6, 2 and 6, and 3 and 6) are able to downregulate and stabilize x5, whereas drug 6
alone cannot do so. Using drug 6 alone results in oscillations in x5, causing a violation of the constraint of Eq. (6c). More
interestingly, the optimal application of the drugs reveals a clear sequential protocol: first apply a drug other than drug 6 (1,
2, or 3) to suppress oscillations (see Figs. 5H, L and P), then apply drug 6 to drive AV count down to the desired level. The
combination of drugs 1 and 6 is peculiar in that in this case application of drug 1 drives the system out of the oscillatory regime
(Fig. 5O) but also upregulates autophagy; subsequent application of drug 6 is effective in downregulating autophagy.
It is important to emphasize that the two drugs acting together in any given combination therapy are, for simplicity, modeled
as non-interacting, which may or may not be reasonable, depending on the mechanisms of actions of specific drugs of interest.
The drug synergies detected in our analyses arise from the nonlinear dynamics of the regulatory network controlling autophagy.
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Without the formal framework presented here for therapy design, it would arguably be difficult to identify these synergies.
Discussion
Here, we have taken up the problem of designing targeted therapies to control a cellular phenotype of cancer cells, namely, their
commitment to recycling of cytoplasmic contents through the process of autophagy, as measured by cellular autophagic vesicle
(AV) count. Autophagy generates building blocks needed for de novo protein synthesis in support of growth (and proliferation).
Modulation of autophagy, up or down, in autophagy-addicted cancer cells has the potential to selectively kill these cells26.
Our approach was to first construct a mathematical model for autophagy regulation that captures the effects of key
physiological stimuli—changes in the supplies of energy and nutrients—and the idealized effects of six available drug types
(Eq. (1), Figs. 1–3) and to then pose the question of therapy design as a constrained, optimal control problem (Eqs. (4)–(6)).
Numerical solution of this problem, through optimization of a control input accounted for in the model (i.e., an adjustable
time-dependent drug injection/input rate), yielded monotherapy drug schedules that require a minimum amount of drug,
maintain drug concentration below a specified threshold at all times, and that bring about desired effects in the most efficient
manner possible (Fig. 4), in a well-defined sense. Furthermore, through the essentially same approach, but with consideration
of adjustable time-dependent drug injection/input rates for two different drugs, we were able to predict synergistic drug pairs
(Fig. 5).
Optimal monotherapies were found to entail intermittent pulses of drug injection/input at irregular, non-obvious intervals
and doses (Fig. 4). These features of optimal drug schedules—the pulsatile nature of drug administration and the irregularity of
drug administration in terms of both timing and dosage—appear to be generic and each is discussed in further detail below.
The pulsatile nature of optimal monotherapy arises from the optimal control problem that we posed (Eqs. (4)–(6)), which
can be viewed as a minimum-fuel problem, in that our control problem calls for usage of a minimal total amount of drug. The
rationale for this control objective is that drugs typically have dose-dependent offtarget effects, which may contribute to drug
toxicity. Thus, by seeking drug schedules that achieve desired endpoints while using only a minimal total amount of drug, we
seek to mitigate the possible negative consequences of offtarget drug effects. Mathematically, our minimum-fuel objective
function, Eq. (5), leads to pulsatile drug administration because the Hamiltonian of the optimal control problem is linear in
the control inputs ui(t), i ∈ Tk (see “Pseudo-Spectral Optimal Control” in Supplementary Methods for a detailed derivation).
Optimal control problems which have Hamiltonians that are linear in the control input are well-known to have singular arcs,
that is, discontinuities jumping between upper and lower bounds of the control input (see Chapter 5 in Kirk50 for the derivation
of singular arc behavior and the brief overview of this issue in “Pseudo-Spectral Optimal Control” in Supplementary Methods).
Because we do not impose an upper bound on ui(t), the discontinuities we expect to see are Dirac delta type functions, a
pulse of infinite magnitude but infinitesimal width. With the use of numerical methods to find solutions of the optimal control
problem, we cannot capture the Dirac delta behavior exactly. Instead, we see finite pulses of finite width, which, while likely
suboptimal, are more physically realistic.
Although pulses of drug input are consistent with convenient drug delivery modalities, such as oral administration of a
drug in pill form or intravenous injection, optimal schedules do not entail uniform drug doses, nor uniform periods of drug
administration. This irregular nature of optimal drug administration depends on the structure of the nonlinear cellular network
that controls the synthesis of AVs. In particular, in our model, each drug specifically targets individual nodes of the cellular
network, and therefore, different drugs play dynamically distinct roles and cannot be treated as equivalent control inputs. Thus,
it may be critically important to better understand the interplay between targeted therapies and archetypical cellular regulatory
network dynamics if we are to design the best possible therapies for populations of patients. Because network dynamics can
be expected to vary between patients, patient-specific variability in network dynamics, which we have not considered in our
analyses here, is a factor that likely affects the efficacy of individualized targeted therapy and that therefore should receive
attention in future studies. The study of Fey et al.54 points to the feasibility of considering patient-specific parameters in
mathematical models. In this study, gene expression data available for individual patients were used to set the abundances
of gene products in patient-specific models for a cell signaling system. Because mutations can be detected in the tumors of
individual patients, effects of oncogenic mutations could also potentially be accounted for in patient-specific models. The
study of Rukhlenko et al.6 provides an example of a study where the effects of an oncogenic mutation were considered in a
mathematical model. In the study of Fröhlich et al.55, gene expression and mutational profiles were both considered in cell
line-specific models.
The therapy design approach presented here is flexible and allows for the evaluation of drug combinations. In our analyses,
we focused on dual therapies. Somewhat surprisingly, we found several drug pairs that together are more effective than either
drug alone (according to our model). These pairs are drug 2 and drug 6 when CNu = CEn = 0.1 (severe energy/nutrient stress)
and the combination of drug 6 with drug 1, 2, or 3 when CNu = CEn = 0.6 (moderate energy/nutrient stress). In the latter cases,
drug 6 alone is incapable of downregulating autophagy to the desired level, but it sensitizes the network to drugs 1–3 when
one of these drugs is used in conjunction with drug 6. According to the model (and its parameterization), the most potent
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synergistic drug pair is the combination of drugs 2 and 6. With this combination, the total amount of drug 2 used was reduced
by more than 5-fold (see the Supplementary Note and Supplementary Fig. S5) in comparison to the case where drug 2 is used
optimally in isolation. More striking perhaps is that drug 6 when used alone is incapable of achieving the performance objective.
Interestingly, our results provide mechanistic insight into the optimal sequence of drug delivery: therapy is optimal when drug
2 is injected about 80 minutes earlier than drug 6. That is, the best outcome was achieved when first inhibiting MTORC1,
thus halting the intrinsic oscillations of the network dynamics, and then only inhibiting VPS34 to reduce synthesis of AVs. It
should be noted that in our evaluation of this drug pair, we have assumed that there is no interaction between drugs 2 and 6, an
idealization that may not be appropriate for specific examples of drugs of these types.
The same optimal control approach that we have demonstrated for 2-drug combinations can be applied for combinations
involving more than two drugs. Indeed, our approach was presented for the general case of k drugs used in combination.
Our expectation is that effective combinations involving more than two drugs may be more likely to exist than effective
combinations involving only two drugs, because controllability would presumably increase with the availability of more drugs.
However, finding an effective combination may be more computationally expensive because of the larger number of possible
combinations, and 2-drug combinations may be preferable to higher-order combinations because of drug side effects.
As reported by Palmer and Sorger56, many clinically used drug combinations are effective for reasons other than drug
synergy, which is rare. In essence, the majority of clinically available drug combinations are, for all intents and purposes,
equivalent to monotherapy at the level of individual patients. The basis for their effectiveness at the population level is simply
that tumors in different subpopulations of patients have distinct drug sensitivities. Thus, new methods for predicting promising,
non-obvious synergistic drug combinations, such as the approach reported here, could be helpful in developing combination
therapies that derive their effectiveness from drug synergy. Synergistic drug combinations would seemingly offer significant
benefits over monotherapy, or what is effectively monotherapy, in terms of delaying or perhaps eliminating the emergence of
drug resistance. We note that our analysis identified synergies between pairs of drugs that are predicted to manifest without fine
tuning of the doses used or the timing of drug administration. We admit that these predictions could perhaps have been found
through an ad hoc model analysis. Nevertheless, we see value in leveraging an optimal control framework for model analysis,
even if an optimal control strategy is not sought, because with this type of approach it is less likely that interesting behavior will
be missed.
There is presently cautious optimism that effective drug combinations will be identified through high-throughput screening
experiments57, or through learning from data. However, the sheer number of possible drug combinations poses a barrier to
experimental discovery of efficacious drug combinations and it is not clear that the data requirements of machine learning
approaches can be met in the near term. Thus, it is important to consider alternatives, such as the approach presented here, which
leverages available mechanistic understanding of how regulatory protein/lipid kinases influence the synthesis of AVs, which
we have consolidated in the form of a mathematical model (Eq. (1)), designed to be useful for computational characterization
of drug combinations. We note that our model was formulated specifically for this purpose, and it was not designed to
make predictions outside this limited domain of application. Indeed, to facilitate our computational analyses, the model was
handcrafted to be as simple as possible while still reproducing key behaviors of more mechanistically detailed models33, 34. This
approach was helpful in making calculations feasible. Unfortunately, to our best knowledge, there are no proven approaches for
systematically and automatically deriving a suitable surrogate model for therapy design from a more detailed, mechanistic
model of a cellular regulatory network. Pursuit of such a capability seems like an important subject of future research.
Our intent at the start of this study was to investigate how control engineering concepts might be introduced into formal
therapy design. Thus, we have only attempted to demonstrate that our methodology is capable of generating interesting (and
testable) predictions of effective drug schedules and drug combinations. Development of novel therapies will, of course,
require experimental validation of candidate combinations, which is beyond the intended scope of the present study. Thus, we
caution that our predictions of optimal drug schedules and synergistic drug combinations are only intended to demonstrate
methodology. The merit of this methodology is not in reaching final conclusions but in prioritizing experimental efforts and
thereby accelerating experimental validation of targeted therapies. Because kinase inhibitors of each type considered in our
analysis are available for experimental characterization and autophagy is a cellular phenotype that can be readily assayed,
as in the study of Martin et al.34 or du Toit et al.58, a logical next step would be to probe for the predicted drug synergies
in cell line experiments. It might be especially interesting to evaluate a combination of an ULK1-specific inhibitor, such as
ULK-10159, and a VPS34-specific inhibitor, such as VPS34-IN160. We predict that this combination will be synergistic, and the
combination targets the two kinases considered in our analysis that are most proximal to the cellular machinery for producing
autophagosomes. On the computational side, to increase confidence in predictions, sensitivity analysis techniques tailored for
optimal control problems could be applied to characterize the robustness of predictions61, 62, and experimental design techniques
could be applied to aid in generating data useful for reducing parameter uncertainty63, 64. Several studies strongly support the
potential value of formal therapy design65–67, and the main contribution here is a new approach to this subject. Two important
distinguishing features of this approach are 1) the consideration of a mathematical model for a cellular regulatory network that
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controls a cellular phenotype and 2) application of sophisticated methods from automatic control theory.
Methods
Simulations
Simulations were performed by numerical integration of the model ODEs. The parameter settings used in calculations are
provided in the Supplementary Tables S1 and S2.
Pseudo-Spectral Optimal Control
Optimal control as a field of research combines aspects of dynamical systems, mathematical optimization and the calculus of
variations50. Together Eqs. (5) and (6) form a constrained optimal control problem, which can generally be written as,
min
u(t)
J(x(t),u(t), t) =
∫ tf
t0
F (x(t),u(t), t) dt
s.t. x˙(t) = f(x(t),u(t), t)
eL ≤ e(x(t0), x(tf ), t0, tf ) ≤ eU
hL ≤ h(x(t),u(t), t) ≤ hU
t ∈ [t0, tf ]
(8)
In general, there exists no analytic framework that is able to provide the optimal time traces of the controls and the states in Eq.
(8), and so we must resort to numerical techniques.
Pseudo-spectral optimal control (PSOC) has become a popular tool in recent years68, 69 that has allowed scientists and
engineers solve optimal control problems like that of Eq. (8) reliably and efficiently in applications such as guiding autonomous
vehicles and maneuvering the international space station69. The main concepts of PSOC are summarized here but are explained
at length in “Pseudo-Spectral Optimal Control” in Supplementary Methods. See also Supplementary Fig. S11. We define a set
of N discrete times {τi} i = 0, 1, . . . , N where τ0 = −1 and τN = 1 with a mapping between t ∈ [t0, tf ] and τ ∈ [−1, 1].
The choice of {τi} is key to the convergence of the full discretized problem and so typically they are chosen as the roots of an
N + 1th order orthogonal polynomial such as Legendre or Chebyshev. In fact, the type of PSOC one uses is typically named
after the type of polynomial used to generate the discretization points. Let xˆ(τ) =
∑N
i=0 xˆiLi(τ) be an approximation of
x(τ) where Li(τ) is the ith Lagrange interpolating polynomial. The dynamical system is approximated by differentiating the
approximation xˆ(τ) =
∑N
i=0 xˆiLi(τ) with respect to time.
dxˆ
dτ
=
N∑
i=0
xi
dLi
dτ
(9)
Let Dk,i = ddτLi(τk) so that we may rewrite the original dynamical system constraint in Eq. (8) as the following set of
algebraic constraints.
N∑
i=0
Dk,ixi − tf − t0
2
f(xˆi, uˆi, τi) = 0, k = 1, . . . , N (10)
With the original time-varying states and control inputs now discretized, the dynamical equations approximated with
Lagrange interpolating polynomials, and the cost function approximated by a quadrature, the discretized optimal control
problem can be expressed as the following nonlinear programming (NLP) problem.
min
ui
i=0,...,N
Jˆ =
tf − t0
2
N∑
i=0
wif(xˆi, uˆi, τi)
s.t.
N∑
i=0
Dk,ixˆi − tf − t0
2
f(xˆk, uˆk, τk) = 0, k = 0, . . . , N
eL ≤ e(xˆ0, xˆN , τ0, τN ) ≤ eU
hL ≤ h(xˆk, uˆk, τk) ≤ hU , k = 0, . . . , N
ti =
tf − t0
2
τi +
tf + t0
2
(11)
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We used PSOPT 35, an open-source PSOC toolbox written in C++, to perform the PSOC discretization procedure.
The NLP problem of Eq. (11) can be solved with a number of different techniques, but here we use an interior point
algorithm70 as implemented in the open-source C++ software Ipopt71.
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Figure 1. Schematic diagram of a minimalist mathematical model for regulation of autophagy and the effects of targeted drug
interventions. The model accounts for two physiological inputs (energy and nutrient supply) and regulatory influences,
stimulatory or inhibitory, within a network of interacting kinases. Each kinase is taken to have a constant total abundance and
to be dynamically distributed between active and inactive forms. The active fractions of MTORC1, ULK1, AMPK, and VPS34
are represented by x1, x2, x3 and x4, respectively. Targeted drugs, denoted by red ovals, promote kinase inactivation or
activation as indicated. Six drug types are considered: 1) a kinase inhibitor specific for MTORC1, 2) a kinase inhibitor specific
for both MTORC1 and VPS34, 3) an ULK1 kinase inhibitor, 4) an allosteric activator of AMPK, 5) an AMPK kinase inhibitor,
and 6) a VPS34 kinase inhibitor. The supplies of cellular energy and nutrients (CEn and CNu), together with drug
concentrations (w1, . . . , w6), determine the kinase activities of MTORC1, ULK1, AMPK, and VPS34 and thereby the rate of
synthesis of autophagic vesicles (AVs). The control parameters are drug injection/input rates (u1, . . . , u6). Note that drug
clearance is not indicated in this diagram but is considered in the model equations.
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Figure 2. Predicted dependence of AV count on energy and nutrient supplies according to the model for autophagy regulation
(Eq. (1)). (A) Long-time behavior. In this panel, the stationary or time-averaged value of x5(t) for constant supplies of energy
and nutrients as t→∞ is indicated by color over the full ranges of the two physiological inputs of the model: energy supply
(CEn) and nutrient supply (CNu). It should be noted that we take the most extreme energy/nutrient starvation conditions to
correspond to CEn = CNu = 0, and we take the most extreme energy/nutrient replete conditions to correspond to
CEn = CNu = 1. The solid black curves delimit the regions where long-time behavior of x5 is oscillatory or not. If behavior is
oscillatory, the time-averaged value of x5 is reported; otherwise, the stationary value is reported. A bifurcation analysis
indicates that long-time behavior is characterized by a stable fixed point, the coexistence of a stable fixed point and a stable
limit cycle, or a stable limit cycle. The region labeled ‘oscillatory’ indicates the conditions for which a stable limit cycle exists;
however, this diagram is not intended to provide a full characterization of the possible qualitative behaviors and bifurcations of
Eq. (1). As indicated by the color bar, the (average) AV count varies over a range of roughly 2 to 37 vesicles per cell. (B–E)
Transient behavior. Each of these plots shows x5 as a function of time t after a coordinated change in energy and nutrient
supplies. The plot in panel B shows the predicted response to a steep, step increase in stress level, i.e., a change in conditions
from CEn = CNu = 1 to 0.2. The plot in panel C shows the predicted response to a moderate, step increase in stress level, i.e.,
a change in conditions from CEn = CNu = 1 to 0.6. The plot in panel D shows the predicted response to a moderate, step
decrease in stress level, i.e., a change in conditions from CEn = CNu = 0.2 to 0.6 The plot in panel E shows the predicted
response to a steep, step decrease in stress level, i.e., a change in conditions from CEn = CNu = 0.2 to 1.
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Figure 3. Predicted dependence of AV count (x5) on drug dose according to Eq. (1). In each panel, we show the long-time
effects of monotherapy with drug i ∈ {1, . . . , 6}; the drug considered in each panel is maintained at the constant
(dimensionless) concentration indicated on the horizontal axis. Drugs 1–6 are considered from top to bottom. Responses to
drugs depend on the supplies of energy and nutrients. The left panels (A–F) correspond to conditions for which
CNu = CEn = 0.1 (severe energy/nutrient stress), and the right panels (G–L) correspond to conditions for which
CNu = CEn = 0.6 (moderate energy/nutrient stress). The long-time behavior of x5 under the influence of monotherapy can be
stationary (with a stable fixed point) or oscillatory (with a stable limit cycle). The shaded regions indicate where there is
oscillatory behavior. At a given drug dose, the top and bottom bounds of a shaded region delimit the envelope of oscillations
(i.e., the maximum and minimum values of x5).
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Figure 4. Best performing monotherapies. (A–D) Panels A–D are from a numerical experiment for which we set
CNu = CEn = 0.1 and attempt to use drug 4 to downregulate the AV count. (E–H) Panels E–H from a numerical experiment
for which we set CNu = CEn = 0.6 and attempt to use drug 2 to downregulate the AV count. (I–L) Panels I–L are from a
numerical experiment for which we set CNu = CEn = 0.6 and attempt to use drug 5 to upregulate the AV count. The plots in
the first column are cumulative drug dosages for the monotherapies considered. The plots in the second column are the drug
concentrations. The plots in the third column show x5(t) and the plots in the fourth, or rightmost, column show x1(t), x2(t),
x3(t), and x4(t) that we are making no attempt to control. In all simulations, the upper bound on the allowable concentration of
drug i, wmaxi , was set at 2. For panels A–H, the target AV count was 10 (i.e., x
f
5 = 10). For panels I–L, the target AV count was
37 (i.e., xf5 = 37). The white region corresponds to the time interval [t0, tf ] when we either upregulate or downregulate the AV
count The shaded region corresponds to the time interval [t0, tf ] when the AV count is maintained within the interval x
f
5 ± .
17/13
0 120 240
0
2
4
A
r∗6,2(t)
r∗2,2(t)
0 120 240
0
0.5
1
1.5
2
B
w6(t) w2(t)
0 120 240
10
20
30
37
C
A
V
s
0 120 240
0
0.5
1
D
x
i
(t
)
x1(t)
x2(t)
x3(t)
x4(t)
0 120 240
0
2
4
E
r∗6,2(t)
r∗2,2(t)
0 120 240
0
0.5
1
1.5
2
F
w6(t) w2(t)
0 120 240
10
20
30
37
G
A
V
s
0 120 240
0
0.2
0.4
0.6
0.8
1
H
x
i
(t
)
x1(t)
x2(t)
x3(t)
x4(t)
0 120 240
0
2
4
I
r∗6,2(t)
r∗3,2(t)
0 120 240
0
0.5
1
1.5
2
J
w6(t) w3(t)
0 120 240
10
20
30
37
K
A
V
s
0 120 240
0
0.2
0.4
0.6
0.8
1
L
x
i
(t
)
x1(t)
x2(t)
x3(t)
x4(t)
0 120 240
0
2
4
M
Time (t) (min)
r∗6,2(t)
r∗1,2(t)
0 120 240
0
0.5
1
1.5
2
N
Time (t) (min)
w6(t) w1(t)
0 120 240
10
20
30
37
O
Time t (min)
A
V
s
0 120 240
0
0.2
0.4
0.6
0.8
1
P
Time t (min)
x
i
(t
)
x1(t)
x2(t)
x3(t)
x4(t)
Figure 5. Optimal dual therapies. (A–D) Panels A–D are from a numerical experiment for which we set CNu = CEn = 0.1 and
attempt to use a combination of drugs 2 and 6. (E–H) Panels E–H are from a numerical experiment in which we set
CNu = CEn = 0.6 and attempt to use a combination of drugs 2 and 6. (I–L) Panels I–L are from a numerical experiment in
which we set CNu = CEn = 0.6 and attempt to use a combination of drugs 3 and 6. (M–P) Panels M–P are from a numerical
experiment in which we set CNu = CEn = 0.6 and attempt to use a combination of drugs 2 and 6. The plots on the first column
are cumulative drug dosages for the dual therapies considered. The plots on the second column are drug concentrations. The
plots in the third column show x5(t) and the plots in the fourth, rightmost, column show x1(t), x2(t), x3(t), and x4(t), which
we did not attempt to control. In all the simulations, the target value for AV count was 10 (i.e., xf5 = 10) and the upper bound
on each drug concentration wi was 2 (i.e., wmaxi = 2). The white region corresponds to the time interval [t0, tf ] when we either
upregulate or downregulate the AV count The shaded region corresponds to the time interval [t0, tf ] when the AV count is
maintained within the interval xf5 ± .
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Supplementary Methods
Formulation of the Model
Formulation of Eq. (1) was guided by the models of Szyman´ska et al.1 (Ref. 33 in the main text) and Martin et al.2 (Ref. 34 in
the main text) mainly as follows. The model of Eq. (1) was formulated and parameterized so as to allow the model to predict
oscillatory induction of autophagy in response to intermediate drug, energy, and nutrient stress inputs (as illustrated in Figs. 2
and 3), in accord with the predictions of the model of Szyman´ska et al.1. Moreover, as in both models considered by Martin et
al.2, Eq. (1) takes AVs to be turned over constitutively via a pseudo first-order degredative process. Another factor that drove
model formulation and parameterization was the availability of measured AV dynamics induced by MTORC1 inhibition2. Eq.
(1) was parameterized so as to reproduce the essential aspects of these dynamics (see below for more discussion).
Equation (1) differs from the earlier models of Szyman´ska et al.1 and Martin et al.2 mainly as follows. In the model of
Szyman´ska et al.1, the regulatory influences depicted in Fig. 1 (e.g., mutual inhibition of MTORC1 and ULK1 and negative
feedback from ULK1 to AMPK) are not explicitly represented, as is the case in the model of Eq. (1), where regulatory influences
on enzymatic activities are represented explicitly using Hill functions. Rather, in the model of Szyman´ska et al.1, regulatory
influences emerge from formal representations of the biomolecular interactions considered in the model, which are termed
rules3. In other words, Eq. (1) provides a model of regulatory influences and their effects, whereas the model of Szyman´ska et
al.1 provides a model of biomolecular interactions and their effects, which include emergent regulatory influences. The rules of
the model of Szyman´ska et al.1 can be processed automatically by the BioNetGen software package4 to obtain a system of 173
coupled ordinary differential equations (ODEs). These equations account for various complexes (e.g., a complex of AMPK and
ULK1 that is generated when AMPK docks to a particular site in ULK1) and protein phosphoforms. In contrast, the model of
Eq. (1) does not track these details. Rather, it simply tracks the activities of AMPK, MTORC1, and ULK1 (and also the activity
of VPS34, which was not considered by Szyman´ska et al.1). In the model of Szyman´ska et al.1, AMPK, MTORC1, and ULK1
each has numerous states. In contrast, in the model of Eq. (1), these protein states are reduced to just two for each protein:
active or inactive.
Although the model of Szyman´ska et al.1 provides a mechanistically detailed representation of biomolecular interactions, it
does not include a representation of autophagic vesicle (AV) population dynamics. To include a representation of AV population
dynamics in Eq. (1), we started with the simple representation of AV production and clearance used in the AV population
dynamics model of Martin et al.2:
dV
dt
= P ∗ − cV,
where V is cellular AV count, P ∗ is a condition-dependent zero-order rate constant for AV production, and c is a pseudo
first-order rate constant for clearance of AVs. In our model, we modified this equation by allowing the production rate to be
time dependent. In Eq. (1) the rate of AV production is a linear function of VPS34 activity, x4(t). In other words, the rate of
AV production is given by k3x4(t) (vs. a constant, P ∗).
Parameter settings are summarized in Supplementary Tables S1 and S2. These settings are not uniquely determined by data;
they were guided by the considerations explained below.
Parameter settings for parameters in the h and H Hill functions were determined first, as follows. For each Hill function,
we initially set rb = 0, rm = 1, θ = 0.5, and n = 2. (We omit indices in referring to these parameters for convenience.) We
then varied parameter values (by hand tuning) to obtain qualitative behavior consistent with that predicted by the model of
Szyman´ska et al.1. The behaviors of the two models are compared directly in Supplementary Fig. S1. In panels A and B of
Supplementary Fig. S1, AV count (x5) and ULK1 activity (x2) are shown, respectively, as a function of time. Initially, in these
plots, we consider a nutrient/energy replete condition (CEn = CNu = 1) without rapamycin (or any other drug). A low dose of
rapamycin is added at time t = 100 min and then a high dose of rapamycin is added at time t = 200 min. As can be seen, x5
(Supplementary Fig. S1A) and x2 (Supplementary Fig. S1B) initially have steady low values. After the initial introduction of
rapamycin, these quantities begin to oscillate. After the second addition of rapamycin, the two quantities have steady high
values. This behavior is qualitatively the same as the behavior predicted by the model of Szyman´ska et al.1 (Supplementary
Fig. S1C). It should be noted that the study of Szyman´ska et al.1 did not establish that the AMPK-MTORC1-ULK1 network
actually exhibits oscillatory behavior; this study only showed that oscillatory behavior is a possible consequence of known
regulatory mechanisms. By requiring Eq. (1) to reproduce the qualitative nonlinear dynamics of the model of Szyman´ska et
al.1, we made the optimal control problem considered here more of a challenging test of our methodology.
Next, parameter settings for the rate constants k1, k2, k3 and k4 were determined (again through hand tuning). In the
study of Martin et al.2, AV population dynamics were monitored after cells in a nutrient/energy replete condition were treated
with a dose of rapamycin or AZD8055 (a catalytic MTOR inhibitor) sufficient to fully inhibit MTORC1 activity. We selected
values for the rate constants that allow the model of Eq. (1) to roughly reproduce the observed dynamics induced by MTORC1
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inhibition in the study of Martin et al.2. The behaviors predicted by Eq. (1) and the model of Martin et al.2 are directly
compared in panels D and E of Supplementary Fig. S1. The AV population dynamics model of Martin et al.2 can be written as
follows: dV/dt = (1 + kδ)P − cV , where δ = 0 indicates a 0 dose of MTORC1 inhibitor, δ = 1 indicates a saturating dose of
MTORC1 inhibitor, P is the baseline rate of AV production, and (1 + k)P is the induced rate of AV production stimulated by a
saturating dose of MTORC1 inhibitor. By varying δ from 0 to 1, we obtain the plots shown in Supplementary Fig. S1E. Note
that AV dynamics at intermediate values for δ are not oscillatory, as we would expect from the analysis of Szyman´ska et al.1. In
contrast, Eq. (1) does predict oscillatory AV dynamics at intermediate doses of MTORC1 inhibitor (Supplementary Fig. S1D).
Importantly, as desired, Eq. (1) makes predictions that are in qualitative agreement with the model of Martin et al.2, in that
both models predict that AV dynamics stimulated by MTORC1 inhibitor treatment unfold on a similar timescale and that the
maximal range of regulation is similar. In Supplementary Fig. S2, we directly compare the AV dynamics predicted by Eq. (1)
with AV dynamics measured by Martin et al.2. As can be seen, Eq. (1) is roughly consistent with the data.
Finally, parameter settings for the drug clearance rate constants in Eq. (1) (δ1, . . . , δ6) were set in accordance with measured
drug lifetimes reported in the literature, which have half-lives ranging from approximately 1 to 40 h. See Supplementary Table
S2 and references cited therein. With this approach, the different drugs considered have different pharmacokinetics, arguably
making the optimal control problem more realistic.
Pseudo-Spectral Optimal Control
We present here a brief overview of the theory of pseudo-spectral optimal control (PSOC). Before discussing the PSOC
framework, we briefly review optimal control as well as the difficulties that arise when attempting to solve a general optimal
control problem (OCP) analytically. Afterwards, we describe how PSOC discretizes the OCP, approximating the original OCP
as a nonlinear programming (NLP) problem. Approximating the original problem as an NLP is beneficial because there exists a
vast literature and many pieces of software capable of solving large-scale NLPs efficiently. Finally, we discuss our choices of
software, all of which are open-source, and briefly discuss the algorithms they implement.
Optimal Control
The field of optimal control combines aspects of dynamical systems, optimization, and calculus of variations5. In words, an
optimal control problem is solved by finding a time varying control input u(t) that minimizes a quantity J(x,u, t) subject to a
system’s dynamics and other constraints.
General Problem
Define the states of the system as x(t) ∈ Rn, the control inputs as u(t) ∈ Rm, and time t ∈ [t0, tf ] where t0 < tf . The typical
form of an optimal control problem for a continuous-time system can be written as,
min
u(t)
J(x(t),u(t), t) = E (x(t0), x(tf ), t0, tf ) +
∫ tf
t0
F (x(t),u(t), t) dt
s.t. x˙(t) = f(x(t),u(t), t)
eL ≤ e(x(t0), x(tf ), t0, tf ) ≤ eU
hL ≤ h(x(t),u(t), t) ≤ hU
t ∈ [t0, tf ]
(S1)
The objective function (or cost function) J(x,u, t) is composed of two parts, (i) E : Rn × Rn × R× R 7→ R which is a cost
associated with the endpoint behavior of the system x(t0) and x(tf ), and (ii) F : Rn × Rm × R 7→ R which is a running cost
over the entire time interval [t0, tf ]. The system dynamics is described by the function f : Rn × Rm × R 7→ Rn. Constraints
on the endpoints (x(t0) and/or x(tf )) are described by e : Rn × Rn × R× R 7→ Re. While we only specify initial conditions,
more complicated relations between the endpoints of the states can be specified as well. Finally, path constraints, such as
bounds on the states or control inputs, are described by h : Rn × Rn × R 7→ Rh.
Notation for Therapies
Let D = {1, 2, 3, 4, 5, 6} denote the possible drugs we may use (described in the main text) and Tk ⊆ D denote the drugs
chosen for our therapy such that |Tk| = k. Let w(t) ∈ Rk denote the drug concentrations and u(t) ∈ Rk denote the drug
injection rates for only those drugs chosen to be in the therapy. For example, if we consider the dual therapy T2 = {3, 6}, then
w(t) =
[
w3(t)
w6(t)
]
, u(t) =
[
u3(t)
u6(t)
]
(S2)
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Those drugs not chosen to be in Tk are denoted D\Tk. In the example where Tk = {3, 6}, those drugs not used are
D\Tk = {1, 2, 4, 5}. If a drug i ∈ D\T then we set wi(t) = 0 for all time t.
The drug concentrations appear in the dynamical equations as inhibitory Hill functions H(wi(t)).
H(wi(t)) = rm,i − (rm,i − rb,i) w
ni
i (t)
wnii (t) + θ
ni
(S3)
Note that if i /∈ Tk, then, as stated previously, wi(t) = 0, and so, by Eq. (S3), H(wi(t)) = 1 for all time t.
The Minimum Drug OCP
In the main text, we present a multi-phase optimal control problem, i.e., two optimal control problems linked together by
enforcing continuity at their interface. Despite this added complexity, we can develop a set of necessary conditions for each
phase individually and so for now we focus on the single phase problem. We will return to the multi-phase problem in the next
section that covers the discretization procedure.
Either phase of the OCP presented in the main text can be mapped to the general formulation presented in Eq. (S1) with the
following definitions.
• The state variables x(t) = [ x1(t) x2(t) x3(t) x4(t) x5(t) wT (t) ]T ∈ R5+k and the control input u(t) ∈ Rk
so that n = 5 + k and m = k.
• The cost function J = ∫ tf
t0
ui(t)dt (see Eq. (1) in the main text) so that, from Eq. (S1), E ≡ 0 and F =
∑
i∈T ui(t).
• The system dynamics, as presented in Eq. (1), are rewritten here,
x˙(t) =

x˙1(t)
x˙2(t)
x˙3(t)
x˙4(t)
x˙5(t)
w˙(t)
 = f(x(t),u(t)) = f¯(x(t)) +Bu(t)
=

(1− x1)CNuH(w1)H(w2)− x1h12(x2)h13(x3)
(1− x2)h23(x3)H(w3)− x2h21(x1)
(1− x3)k1H(w4)− CEnx2x3H(w5)
(1− x4)h42(x2)H(w2)H(w6)− k2x4
k3x4 − k4x5
−∆w(t)
+

0Tk
0Tk
0Tk
0Tk
0Tk
Ik
u(t)
(S4)
where 0k is a vector of all zeros of length k, Ik is the identity matrix of order k, and ∆ is a diagonal matrix with the
corresponding rates δi on the diagonal if i ∈ T . For example, if T = {3, 6}, then
∆ =
[
δ3 0
0 δ6
]
(S5)
Also, note that if i /∈ T , then wi(t) ≡ 0 and H(wi(t)) = 1.
• The only endpoint constraints are set at the initial time,
e(x(t0), x(tf ), t0, tf ) =

x1(0)
x2(0)
x3(0)
x4(0)
x5(0)
w(0)
 , e
L = eU =

x1,0
x2,0
x3,0
x4,0
x5,0
0k
 (S6)
where xi,0 is chosen to either be the steady state value of the system in the absence of control inputs or the time-average
of the time evolution of the system if the dynamics, in the absence of control inputs, is oscillatory. We assume there is no
drug present initially so wi(0) = 0, i ∈ D.
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• Finally, the path constraints consist of upper bounds on the drug concentrations and possibly a lower and/or upper bound
on the AVs.
h(x(t),u(t), t) =
 x5(t)w(t)
u(t)
 , hL =
 xL50k
0k
 , hU =
 xU5wmax1k
∞
 (S7)
where, for the first phase, xL5 = 0 and x
U
5 =∞ but for the second phase we choose xL5 = xf5 −  and xU5 + . Also, the
upper bound on the drug concentration is chosen to be identical for all drugs in the therapy.
Solving Eq. (S1) is not a trivial task, and typically there exists no closed form solution. Instead one typically must turn to
numerical methods, such as PSOC, which we will discuss in the subsequent subsections in some detail. Nonetheless, one
can derive a set of necessary conditions that any solution to Eq. (S1) must satisfy using Pontryagin’s minimum principle5.
Developing these types of necessary conditions allows us to construct a set of validation criteria with which we may test the
quality of any solution returned by our numerical methods.
A full derivation of Pontryagin’s minimum principle is beyond the scope of this work but it is readily available in many
standard texts5. Here, we present the main results surrounding the Hamiltonian constructed from Eq. (S1).
Minimizing the Hamiltonian
Define a vector of time-varying costates (or adjoint variables) as λ(t) =
[
λTx (t) λ
T
w (t)
]T ∈ R5+k so that λx(t) ∈ R5 and
λw(t) ∈ Rk. The Hamiltonian of the OCP in Eq. (S1) is defined as,
H(λ, x,u, t) = F (x,u, t) + λT f(x,u, t)
=
∑
i∈T
ui + λ
T f¯(x) + λBu (S8)
where λ(t) ∈ Rn are the costates (or adjoint variables). A solution to Eq. (S1) must also be a solution of the following
minimization problem.
min
u(t)
H(λ, x,u, t)
s.t. hL ≤ h(x,u, t) ≤ hU
(S9)
To solve Eq. (S9), we define the associated Lagrangian,
H¯(µ,λ, x,u, t) = H(λ, x,u, t) + µTh(x,u, t)
=
∑
i∈T
ui + λ
T f¯(x) + λTBu + µx5x5 + µ
T
ww + µ
T
u u
(S10)
where µ =
[
µx5 µ
T
w µ
T
u
]T ∈ Rh is the copath vector with components associated with the components of the vector of
path constraints in (S7). A solution to Eq. (S9), and thus to our original OCP, must satisfy,
∂H¯
∂u
= 1k +B
Tλ+ µu = 0 (S11)
where the costates evolve according to the dynamical equation,
λ˙ = −∂H¯
∂x
= −
(
∂ f¯
∂x
)T
λ+
 04µx5
µw
 (S12)
The optimal control input ui(t), i ∈ T , must satisfy the complementarity condition6, 7
ui(t) = 0 if µi(t) < 0
ui(t) ≥ 0 if µi(t) = 0
ui(t)→∞ if µi(t) > 0
(S13)
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Combining Eqs. (S11) and (S13), we can relate µu to the time-varying costates by noting from the structure of B, BTλ = λw
so that,
µu(t) = −1k − λw(t) (S14)
Thus, if λwi > −1 then ui = 0, but if λwi = −1, then all we can say is that ui ≥ 0. When λwi > −1, the optimal control is
said to have a singular arc (see chapter 5 in5). Despite the technical difficulties, we have arrived at our first set of validation
conditions, that is,
ui · (λwi − 1) = 0, ∀i ∈ T (S15)
Let us now assume that we have solved Eq. (S9), that is,
H(t) = min
u∈U
H(λ, x,u, t) (S16)
where U is the set of feasible control inputs, i.e., they satisfy all of the constraints imposed by Eq. (S1). The evolution of the
Hamiltonian at the optimal solution can be written,
dH
dt
=
∂H
∂t
(S17)
where, since in our OCP, H does not explicitly depend on time, we expect that dH/dt = 0 and soH should be constant. This
is the second validation condition.
While in the paper and the supplementary sections we display time traces of the states and the control inputs as they are the
quantities of interest to the general reader, we are also able to access the costate and copath time traces, as well as the time
trace of the Hamiltonian. In Fig. S11 we show a typical set of output that we use for measuring the quality of our returned
numerical solution. The sample shows a monotherapy where T = {4}. Panel (a) shows the level of AVs, x5(t), and panel (b)
shows the drug concentration w4(t). Panel (c) contains the copath associated with the level of AVs, µx5(t). Note that during
the first phase when there is no finite bound on x5(t) the copath µx5(t) = 0, while during second phase if µx5(t) 6= 0 then
x5(t) = x
f
5 ± . In panel (d) we plot the other copath µw4(t). The control input u4(t) itself is shown in panel (e) along with
the costate λw4(t) in panel (f). Note that the times at which u4(t) > 0 correspond to times when λw4(t) = −1 as expected.
Panel (g) plots the time evolution of the Hamiltonian evaluated at the optimal solution. Note that the y-axis is scaled by 10−2.
We see thatH ≈ const within each phase, with a jump occurring at the interface between the two phases. As we cannot say
anything about the value of the Hamiltonian at the interface, a discontinuity at this point in time can be expected.
Discretization of the OCP
As presented in the previous subsection, we have seen that the set of necessary conditions which must be satisfied consist of a
system of coupled nonlinear differential equations for x(t) and λ(t) along with a set of non-trivial constraints. Searching for an
analytic solution is unlikely to be successful and so instead we turn to pseudospectral optimal control (PSOC).
In short, PSOC is a methodology by which one may discretize an OCP, approximating the integrals by quadratures and the
time-varying states and control inputs with interpolating polynomials.
The key to PSOC is choosing the discretization points properly. Let {τi}, i = 0, . . . , N , denote the discretization points.
Typically these are chosen as the roots of an orthogonal polynomial such as a Legendre polynomial or a Chebyshev polynomial
of order N . For some popular choices of discretization schemes see8. For concreteness, we will assume that τ0 = −1 and
τN = 1, i.e., we are using a discretization scheme that includes the endpoints and is normalized by the mapping,
t =
tf − t0
2
τ +
tf + t0
2
(S18)
For the discretization scheme chosen, we also compute the associated quadrature weights. For instance, if we choose the roots
of a Legendre polynomial as the discretization scheme, the associated quadrature weights can be found in the typical way for
Gauss quadrature. The time-varying states and control inputs are found by approximating them with a Lagrange interpolating
polynomial.
x(τ) ≈ xˆ(τ) =
N∑
i=0
xˆiLi(τ)
u(τ) ≈ uˆ(τ) =
N∑
i=0
uˆiLi(τ)
(S19)
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The Lagrange interpolating polynomials are defined as,
Li(τ) =
N∏
j=0,j 6=i
τ − τj
τi − τj (S20)
Note that the Lagrange interpolating polynomials satisfy the isolation property, that is, Li(τj) = δi,j . We can thus construct a
set of algebraic equations corresponding to the discretization points {τi}. Define Dk,i = dLidτ (τk) so that the derivative of the
states at the discretization points can be approximated as,
˙ˆx(τk) =
N∑
i=0
xˆiDk,i (S21)
With Eqs. (S19) and (S21), we can approximate the original system of n differential equations as n(N + 1) algebraic equations.
N∑
i=0
Dk,ixˆi − tf − t0
2
f(xˆk, uˆk, τk) = 0n, k = 1, . . . , N
xˆN − xˆ0 −
N∑
k=1
N∑
i=0
wkDk,ixˆi = 0n
(S22)
The last set of algebraic constraints arise from the consistency condition
∫ tf
t0
x˙(t)dt = x(tf )−x(t0). Similarly to the consistency
condition, the integral in the cost function is approximated as,
J =
∫ tf
t0
F (x,u, t) ≈ Jˆ = tf − t0
2
N∑
k=1
F (xˆk, uˆk, τk) (S23)
The discretized approximation of the original OCP is compiled into the following nonlinear programming (NLP) problem.
min
ui
Jˆ =
tf − t0
2
N∑
k=1
F (xˆk, uˆk, τk)
s.t.
N∑
i=0
Dk,ixˆi − tf − t0
2
f(xˆk, uˆk, τk) = 0, k = 1, . . . , N
xˆN − xˆ0 −
N∑
k=1
N∑
i=0
wkDk,ixˆi = 0
eL ≤ e(xˆ0, xˆN , τ0, τN ) ≤ eU
hL ≤ h(xˆk, uˆk, τk) ≤ hU
(S24)
With the above results, we now present the application to the full multi-phase optimal control problem. In general, let us
assume there are p phases where p = 2 in our problem. Each phase is active within the interval t ∈ [t(p)0 , t(p)f ]. In each phase
there is a cost function J (p), a dynamical system f(p), a set of endpoint constraints e(p), and a set of path constraints h(p). If
two phases, p and q, are linked, then there also exists a set of linkage constraints Φ(p,q).
min
u(p)
P∑
p=1
J (p) =
P∑
p=1
∫ t(p)f
t
(p)
0
F (p)(x(p),u(p), t)dt
s.t. x˙(p)(t) = f(p)(x(p),u(p), t)
hL,(p) ≤ h(p)(x(p),u(p), t) ≤ hU,(p)
eL,(p) ≤ e(p)(x(p)(t(p)0 ), x(p)(t(p)f ), t(p)0 , t(p)f ) ≤ eU,(p)
ΦL,(p,q) ≤ Φ(p,q)(x(p), x(q),u(p),u(q)) ≤ ΦU,(p,q)
(S25)
7/26
Each phase is discretized with its own set of points, {τ (p)i } so that,
x(p)(τ) ≈ xˆ(p)(τ) =
N∑
i=1
xˆ(p)i Li(τ) (S26)
so that the full multi-phase NLP is,
min
u(p)i
P∑
p=1
t
(p)
f − t(p)0
2
N∑
k=1
F (p)(xˆ(p)k , uˆ
(p)
k , τk)
s.t.
N∑
i=0
Dk,ixˆ
(p)
i −
t
(p)
f − t(p)0
2
f(p)(xˆ(p)k , uˆ
(p)
k , τk) = 0n, p = 1, . . . , P, k = 1, . . . , N
xˆ(p)N − xˆ(p)0 −
t
(p)
f − t(p)0
2
N∑
k=1
N∑
i=0
wkDk,ixˆi = 0n, p = 1, . . . , P
eL,(p) ≤ e(p)(xˆ(p)0 , xˆ(p)N , t(p)0 , t(p)f ) ≤ eU,(p), p = 1, . . . , P
hL,(p) ≤ h(p)(xˆ(p)k , uˆ(p)k , τk) ≤ hU,(p), k = 1, . . . , N, p = 1, . . . P
ΦL,(p,q) ≤ Φ(p,q)(xˆ(p)0 , uˆ(p)0 , xˆ(q)N , uˆ(q)N ) ≤ ΦU,(p,q), p, q = 1, . . . , P
(S27)
To perform the discretization described in this subsection, we use the open-source C++ PSOC package PSOPT 9.
Next we show that Eq. (S27) can be expressed in the typical NLP form6. Let z(p) contain all of the variables for phase p.
z(p) =

xˆ(p)0
...
xˆ(p)N
uˆ(p)0
...
uˆ(p)N

∈ R(n+m) (S28)
Next, let z contain the variables for every phase,
z =
 z
(1)
...
z(P )
 ∈ R(N+1)(n+m) (S29)
With some algebraic manipulation, the entire discretized multi-phase OCP can be rewritten as an NLP in the typical form.
min
z
c(z)
s.t. g(z) = 0
d(z) ≤ 0
(S30)
To solve the large-scale NLP in Eq. (S30) we employ an interior-point algorithm6. Specific details of the algorithm are outside
the scope of this paper. We used the open-source C++ package Ipopt10 to solve each instance of Eq. (S30). We direct interested
readers who would like to learn more about the technical detailed involved when solving Eq. (S30) to the documentation
provided with Ipopt.
The optimal solution returned, z∗, is separated into its component parts; first by splitting it into the phases z(p)∗, and second
by reconstructing the discrete states and contrlol inputs, xˆ∗i and uˆ
∗
i . The continuous time control inputs and states are then
reconstructed using the Lagrange interpolating polynomials in Eq. (S19). With the continuous time states and control inputs,
x∗(t) and u∗(t), we then verify that the necessary conditions are met to within an acceptable tolerance.
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Supplementary Note
The Response of AVs to Constant Perturbation by Dual Therapies
Before solving the optimal control problem presented in the main text, we explore the capabilities of the dual therapies in terms
of upregulate and downregulate with constant drug concentration as we did in Fig. 3 of the main manuscript. There, we plotted
the long-time response of the system to an individual time-constant drug concentration (w) perturbation for the two sets of
parameters CNu = CEn = 0.1 and CNu = CEn = 0.6. Similarly, in Fig. S3 and S4, we plot the long-time system AV response
for the case of dual therapies with time-constant drug concentration perturbations.
In Fig. S3, we set the parameters CNu = CEn = 0.1. For these parameter values, in the absence of any drugs (control
inputs), the sole attractor of the dynamical system corresponds to a high AV count (≈ 37). Fig. S3 shows the long-time AV
response when the system is perturbed by different combinations of constant inputs. Note that those subsets that contain either
drug 2 or 6 are capable of driving the AVs to zero if wmax is made large enough (pairs {2, 3}, {2, 4}, {2, 6}, {3, 6}, {4, 6},
and {1, 6}). For each pair {i, j}, we set wi = wj and all other values wk = 0, k 6= i and k 6= j. The pair {3, 4} on the other
hand is only capable of driving the AVs to ≈ 10 where any increase of wmax afterwards can produce no further results. Also,
dual therapy {1, 5} is incapable of downregulate .
In Fig. S4, we set the parameters CNu = CEn = 0.6, for which the free evolution of the system is periodic (see Fig. 2
in the main text), and show the same long-time AV response results under constant drug concentration perturbation. For all
dual therapies shown, small drug concentrations are unable to remove the oscillations present (denoted by the shaded regions).
Similar to Fig. S3, we see that all drug combinations that contain either drug 2 or 6 are capable of driving the level of AVs to
zero for wmax set large enough. Also, dual therapy {3, 4}, as before, is only able to reduce the AVs level to ≈ 10 while the
dual therapy {1, 5} instead upregulates the AVs.
Exhaustive Analysis of Two-Drug Combinations
In this section, we present simulation results for all possible dual therapies . First, we set both the parameters CNu = CEn = 0.1
for which the number of AVs at steady state in the absence of control inputs is equal to ≈ 37. We attempt to downregulate
the number of AVs using pairs of drugs from the set {2, 3, 4, 6} so that there are a total of (42) = 6 combinations. A pair of
drugs drawn from this set is called a dual therapy . If {i, j} is a dual therapy , then we say {i} and {j} are its component
monotherapies .
The goal is to investigate our ability to downregulate the number of AVs from the steady state value ≈ 37 to a lower value
in a specified control time interval [0, t0] and, subsequently, to maintain the number of AVs near the target level for a second
time interval [t0, tf ], by using each different dual therapy . We say a dual therapy is viable if it is capable of performing the
goal stated. A dual therapy is deemed efficient if;
• the dual therapy is viable while at least one of its component monotherapies is not, and
• the total amount of drugs provided by the dual therapy is less than either of the component monotherapies .
To compare the efficiencies of the dual therapies we define r∗i,k(t) =
∫ t
0
u∗i (τ)dτ as the total amount of drug i administered at
time t as part of a k = dual or k = mono and introduce the quantities ρi and τi.
0 ≤ ρi =
r∗i,dual(tf )
r∗i,mono(tf )
≤ 1, (S31)
Note that r∗i,dual(tf ) ≤ r∗i,mono(tf ), as otherwise the solution of the dual therapy optimal control problem would be suboptimal
with respect to the case that only drug i is used. We also define the ratio
τi =
t¯i,dual − t¯i,mono
t¯i,mono
(S32)
where t¯i,dual is the time when drug i is activated (that is, the earliest time at which the drug injection rate is nonzero) as a part of
a dual therapy and t¯i,mono is the time when drug i is activated as a monotherapy . Note that τi > 0 (τi < 0) indicates a later
(earlier) activation time of drug i as a part of dual therapy compared to as a monotherapy .
For our simulations, we set the upper bound of the drug concentrations to wmaxi = 2 for each drug i, the time at which
we apply the upper bound to the AVs to t0 = 120 minutes, the time at which we end the simulation to tf = 240 minutes, and
we set the initial condition x(0) to be equal to the steady state solution of the system in the absence of control inputs with
parameters CEn = CNu = 0.1. In Fig. S5, we plot the total drug administered ri(t) =
∫ t
0
ui(τ)dτ in the interval [0, tf ]. The
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plots on the diagonal panels, labeled (ui, ui), correspond to the monotherapies and the plots on the upper triangular panels,
labeled (ui, uj), correspond to the dual therapies . Symmetric to each upper triangular panel (ui, uj), the corresponding lower
triangular panel (uj , ui) contains the values of the ratios ρi and τi in Eqs. (S31) and (S32), respectively.
We notice from Fig. 3A in the main text that the only monotherapies which can downregulate the number of AVs from
≈ 37 to ≈ 10, with wi ≤ 2, is {4}. Thus, the red crosses in panels (u2, u2), (u3, u3) and (u6, u6) in Fig. S5 indicate that those
monotherapies cannot solve the downregulate problem. Clearly, dual therapies {2, 4}, {3, 4} and {4, 6} are viable as drug
{4} as a monotherapy is viable. On the other hand, the dual therapies {2, 3} and {3, 6} are not viable. The most interesting
dual therapy is {2, 6} as neither component monotherapy is viable yet as a pair they are viable Thus by our stated goal and
definitions, the dual therapy {2, 6} is efficient according to our criteria. Also, dual therapy {3, 4} is deemed efficient as the
total consumption of drug 4 is much lower (ρ4 = 0.29) than the total consumption of drug 4 as a monotherapy as shown in
panel (u3, u4) in Fig. S5. We also observe the faster response of drug 4 as a part of the {3, 4} dual therapy than its response as
a monotherapy because τ4 = 0.32 > 0.
In Fig. S6, we consider the dual therapies by combining one of the downregulate drugs, 2, 3, 4 or 6, with one of the
upregulate drugs, 1 or 5. A red cross in a panel again represents a monotherapy or a dual therapy that is not viable. While the
dual therapies {1, 4} and {4, 5} are viable, they are not efficient as neither drugs 1 nor 5 are used (non-zero).
In Fig. S7, we present detailed results when we set the parameters CEn = CNu = 0.6, for which the dynamics in the absence
of control inputs is oscillatory. In our numerical experiments, we attempt to downregulate the number of AVs from its initial
periodic behavior to x5(t0) ≈ 10 and to maintain the number of AVs near that value for the time interval [t0 = 120, tf = 240].
The red cross in panel (u6, u6) indicates the inability of drug 6 as a monotherapy to downregulate the AVs to the desired level.
However, we found this drug to be particularly beneficial when used as a component in a dual therapy . We find that while
all dual therapies are viable, the most efficient dual therapy is {2, 6}, as the total amount of drug 2 required is reduced by
more than five folds when compared to the monotherapy {2}. A comparison with drug 6 alone is not possible as drug 6 as a
monotherapy is not viable. The dual therapy {3, 6} is also efficient by our definition, but only slightly as the amount of drug 3
used is hardly reduced, ρ3 = 0.96. For all other dual therapies , one of the component drugs is never activated so while they
may by viable, we do not consider them efficient.
In Fig. S9, we summarize the results when we attempt to upregulate the number of AVs to ≈ 37 in the same control time
interval [0, t0] and, subsequently, maintain the number of AVs throughout the time interval [t0, tf ] by using dual therapy {1, 5}.
We observe that, while the dual therapy {1, 5} is viable, it is not efficient as drug 1 is never activated and so we must use the
same amount of drug 5 as when it is used as a monotherapy .
In Fig. S10, we consider the dual therapies by combining one of the downregulate drugs, 2, 3, 4 or 6, with one of the
upregulate drugs, 1 or 5. We observe that the dual therapies {1, 6} and {5, 6} are only efficient when CEn = CNu = 0.6.
The other dual therapies while viable are not efficient as the upregulate component (either 1 or 5) is never activated (that is,
non-zero).
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Supplementary Table S1. Parameters of the model (Eq. (1)). See “Formulation of the Model” in Supplementary Methods
for discussion. The parameter values are dimensionless except as indicated.
Parameter Value Parameter Value
rb,12 0 k1 1.00× 10−1
rm,12 1.00× 101 k2 3.00× 10−1
θ12 3.00× 10−1 k3 4.00× 100
n12 4.00× 100 k4 1.00× 10−1
rb,13 0 δ1 3.10× 10−4
rm,13 1.00× 101 δ2 1.93× 10−3
θ13 6.00× 10−1 δ3 5.78× 10−3
n13 6.00× 100 δ4 1.15× 10−2
rb,23 0 δ5 2.31× 10−3
rm,23 6.00× 100 δ6 1.16× 10−3
θ23 1.00× 100 rb 0
n23 4.00× 100 rm 1.00× 100
rb,21 1.00× 10−1 θ 5.00× 10−1
rm,21 6.00× 100 n 2.00× 100
θ21 6.00× 10−1 T 1.00× 100 (min)
n21 4.00× 100
rb,42 1.00× 10−1
rm,42 6.00× 100
θ42 5.00× 10−1
n42 4.00× 100
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Supplementary Table S2. Summary of measured drug half-lives used to set values for the drug clearance rate constants
δ1, . . . , δ6 in Eq. (1). Each half-life, t1/2,i, is the measured half-life of a representative of drug type i. See the references cited
in the table for details about the drugs and measurements.
Drug i Half-life t1/2,i Value (h−1) Rate constant δi Value (min−1) Reference
1 t1/2,1 ∼ 37 δ1 3.10× 10−4 Sato et al.11
2 t1/2,2 ∼ 6 δ2 1.93× 10−3 Baselga et al.12
3 t1/2,3 ∼ 2 δ3 5.78× 10−3 Milkiewicz et al.13
4 t1/2,4 ∼ 1 δ4 1.15× 10−2 Engers et al.14
5 t1/2,5 ∼ 5 δ5 2.31× 10−3 Cameron et al.15
6 t1/2,6 ∼ 10 δ6 1.16× 10−3 Juric et al.16
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Supplementary Fig. S1. Comparison of simulations based on Eq. (1) and simulations based on models of Szyman´ska et
al.1 (Ref. 33 in the main text) and Martin et al.2 (Ref. 34 in the main text). (A) AV dynamics, x5(t), predicted by Eq. (1). The
value of x5 is initially steady and low; the system is perturbed by two additions of rapamycin at time t = 100 and 200 min, as
indicated. (B) Dynamics of ULK1 activity, x2(t), predicted by Eq. (1). The conditions considered are the same as those in
panel A. (C) Dynamics of ULK1 activity predicted by the model of Szyman´ska et al.1. The conditions considered here
correspond qualitatively to those considered in panels A and B. Initially, there is no rapamycin. Later, a low dose of rapamycin
is added. Still later, a high dose of rapamycin is added. Note that the models of Eq. (1) and Szyman´ska et al.1 have different
timescales. This situation is partly a consequence of requiring Eq. (1) to reproduce the AV dynamics measured by Martin et al.2.
Szyman´ska et al.1 showed that the qualitative pattern of behavior illustrated here is a robust feature of known regulatory
interactions among AMPK, MTORC1, and ULK1 (i.e., the pattern of behavior is insensitive to parameter variations).
Furthermore, it should be noted that the model of Szyman´ska et al.1 does not track AVs. Thus, there is no direct comparison to
be made with the time course shown in panel A. (D) AV dynamics predicted by Eq. (1). AV production is stimulated by the
addition of rapamycin at the (dimensionless) doses indicated in the legend. (E) AV dynamics predicted by the model of Martin
et al.2. As in panel D, autophagy is induced by the addition of rapamycin at different doses, as indicated in the legend. For
further discussion, see “Formulation of the Model” in Supplementary Methods.
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Supplementary Fig. S2. Comparison of simulations based on Eq. (1) and data generated by Martin et al.2 (Ref. 34 in the
main text). We parameterized the model of Eq. (1) to roughly reproduce autophagic vesicle (AV) population dynamics reported
by Martin et al.2. Our goal was not to reproduce the observed dynamics exactly but rather to select parameters that yield
induction dynamics on a comparable timescale and a comparable maximal range of regulation. The measured dynamics were
induced by inhibition of MTORC1 using AZD8055, a catalytic MTOR inhibitor. Dynamics were similar when autophagy was
induced using rapamycin2. The curve corresponds to a simulation based on Eq. (1). Each dot corresponds to the average of AV
counts measured in a series of fluorescence microscopy experiments2. The data shown here are taken from Figure 6B in Martin
et al.2. For further discussion, see “Formulation of the Model” in Supplementary Methods.
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Supplementary Fig. S3. The dual therapy long-time response of the system in the case of time-constant drug concentration
perturbations for the parameters CNu = CEn = 0.1. Note that when w is small, the system is oscillatory (represented by the
shaded region in the panels). For each pair of drug, there is some value of w required to overcome the natural oscillatory
behavior of the system.
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Supplementary Fig. S4. The dual therapy long-time response of the system in the case of time-constant drug concentration
perturbations for the parameters CNu = CEn = 0.6.
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Supplementary Fig. S5. The parameter set CNu = CEn = 0.1. The target level of AVs is set x
f
5 = 10 and the maximum
drug concentration is set wmaxi = 2. The diagonal panels represent monotherapies while off-diagonal panels represent dual
therapies . Super-diagonal panels plot the total drug administered and sub-diagonal panels show the efficiency ratios described
in the text of the dual therapies . Those diagonal panels with a red cross correspond to those monotherapies which are not
viable. The only viable monotherapy is {4}, which is shown with a green background. The off-diagonal panel with a red
background for dual therapy {2, 4} is viable, but it is not efficient as drug 2 is not activated. The other three viable dual
therapies , {2, 6}, {3, 4}, and {4, 6} are both viable and efficient, shown with a blue background.
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Supplementary Fig. S6. The parameter set CNu = CEn = 0.1. The target level of the AVs is set to x
f
5 = 10 and the
maximum drug concentration is set to wmaxi = 2. Here we consider those dual therapies which combine one downregulate drug
(2, 3, 4, or 6) with one of the upregulate drugs (1 or 5). Most of the dual therapies are not viable, which is represented with a
red cross. The two viable dual therapies , {1, 4} and {4, 5}, are not viable and so they are shown with a red background.
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Supplementary Fig. S7. The parameter set CNu = CEn = 0.6. The target level of the AVs is set to x
f
5 = 10 and the
maximum drug concentration is set to wmaxi = 2. The diagonal panels (ui, ui) (with a green background) show the total drug
administered for monotherapies . The red cross on the diagonal panel corresponding to monotherapy {6} represents the fact
{6} is not viable. The upper triangular panels (ui, uj), i < j, show the total drugs administered for dual therapies . In the
lower triangular panels (uj , ui), i < j, we compare the dual therapies to their component monotherapies with the efficiency
parameters τ and ρ. A red background in an off-diagonal panel represents those dual therapies which are viable but not efficient
with respect to its component monotherapies . A blue background represents those dual therapies which are both viable and
efficient.
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Supplementary Fig. S8. The parameter set CNu = CEn = 0.6. The target level of the AVs is set to x
f
5 = 10 and the
maximum drug concentration is set to wmaxi = 2. The red crosses on the diagonal panels represents the fact that the
monotherapies {1} and {6} are not viable. On the other hand, the dual therapy {1, 6} is both viable and efficient. The viable
dual therapies composed of two monotherapies which are not viable alone are the type of dual therapies we find most
interesting as they are not obvious when analyzing the monotherapies alone. In the lower triangular panel we compare the dual
therapy to its component monotherapies with respect to the efficiency ratios ρ and τ .
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Supplementary Fig. S9. The parameter set CNu = CEn = 0.6. The target level of the AVs is set to x
f
5 = 10 and the
maximum drug concentration is set to wmaxi = 2. The diagonal panels represent the monotherapies {1} and {5}. A red cross
on the diagonal panel for monotherapy {1} represents the fact {1} is not viable. On the other hand, monotherapy {5} is viable
(shown with a green background). The dual therapy {1, 5} is viable (total drug administered is shown with the red background
in the upper triangular panel) but is not efficient. The inefficiency is shown in the lower triangular panel with the efficiency
ratios ρ5 = 1.
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Supplementary Fig. S10. The parameter set CNu = CEn = 0.6. The target level of AVs is set to x
f
5 = 10 and the
maximum drug concentration is set to wmaxi = 2. Here we consider those dual therapies compose of one downregulate drug (2,
3, 4, or 6), and one upregulate drug (1 or 5). Those panels with a red background represent dual therapies which are viable but
not efficient while the two dual therapies {1, 6} and {5, 6} are efficient. In fact, as seen before, neither the component
monotherapy {6} nor the upregulate drugs are viable for this parameter set, so these efficient dual therapies are particularly
interesting as they could not be found when analyzing the monotherapies alone.
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Supplementary Fig. S11. a) The optimal time evolution of the amount of AVs. b) The optimal time evolution of the drug
concentration w4(t). c) The time evolution of the path covector µx5 associated with the upper bound applied to x5(t). d) The
time evolution of the path covector µw4 associated with the state w4(t). e) The optimal time evolution of the drug u4(t). f) The
costate λw4(t) associated with the state w4(t). g) The time evolution of the lower HamiltonianH. h) The relative local
discretization error at each time t.
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